GenMark Enters Into License Agreement With PerkinElmer For Microfluidics Patent Portfolio
GenMark Diagnostics, Inc. (NASDAQ: GNMK), announced today that it has
entered into a license agreement with PerkinElmer, granting GenMark a
non-exclusive license under PerkinElmer’s microfluidics patent portfolio.
GenMark Diagnostics, Inc. (NASDAQ: GNMK), announced today that it has entered into a license agreement with PerkinElmer, granting GenMark a non-exclusive license under PerkinElmer’s microfluidics patent portfolio. "Completing this agreement strengthens GenMark’s patent portfolio and provides us with maximum flexibility as we expand our menu of high-value multiplex molecular tests and develop new innovative platforms that will deliver superior performance to our customers worldwide,” said Hany Massarany, President and CEO of GenMark Diagnostics. “The use of microfluidics for multiplexed molecular testing is a key enabling platform for personalized health research,” said Kevin Hrusovsky, President, Life Sciences and Technology, PerkinElmer. “We continue to leverage our expansive microfluidics portfolio, through non-exclusive licensing such as the one with GenMark, to extend our market reach and create revenue opportunities in applications and markets that complement our direct channel product offerings.” Financial terms of the agreement were not disclosed. About GenMark Diagnostics, Inc. GenMark Diagnostics is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor® XT-8 system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. GenMark currently markets three tests that are FDA cleared for IVD use: Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, and Thrombophilia Risk Test. A Respiratory Viral Panel (RVP) has been submitted to the FDA for 510(k) clearance. A number of other tests, including HCV Genotyping and 2C19, versions of which are available for research use only, and KRAS, are in development for IVD use. For more information, visit www.genmarkdx.com. About PerkinElmer, Inc. PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $1.9 billion in 2011, has about 7,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com. SAFE HARBOR STATEMENT